Mice Model Market

The report "Mice Model Market by Model Types (Inbred, Outbred, Hybrid), Services (Breeding, Rederivation), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology, Immunology), Application (Research, Drug Discovery) - Global Forecast to 2029", is projected to reach USD 2.2 billion by 2029 from an estimated USD 1.5 billion in 2024, at a CAGR of 8.1% during the forecast period.

Browse 496 market data Tables and 46 Figures spread through 386 Pages and in-depth TOC on "Mice Model Market by Model Types (Inbred, Outbred, Hybrid), Services (Breeding, Rederivation), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology, Immunology), Application (Research, Drug Discovery) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/mice-model-market-1308.html

The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, and growing need for reliable and predictive animal models to facilitate drug discovery and development are the major driving factors of the mice model market. However, the presence of alternative research models, and recent guidelines of U.S.FDA on restriction animal models can hamper market growth.

The inbred mice segment accounted for the largest share by model type in the mice model market in 2023.

By model type, the mice model market has been further categorized into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. Inbred mice accounted for the largest share of the mice model market in 2023. The pivotal role played by genetic uniformity provides consistency and reproducibility, making them ideal for studying complex traits and diseases, contributes significantly to the expansion of this segment within the mice model market.

The CRISPR/Cas9 segment is expected to grow at a higher rate during the forecast period.

Based on technology, the mice model market has been segmented into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, the CRISPR/Cas9 segment accounted for the largest share of the mice model market is expected to grow at a higher growth rate during the forecast period of 2024-2029. CRISPR technology offers a cost-effective solution for generating genetically modified mice compared to traditional methods such as embryonic stem cell-based targeting.

The oncology segment accounted for the largest share of the therapeutic area segment in the mice model market in 2023.

Based on therapeutic area, the mice model market is segmented into oncology, neurology, metabolic diseases, immunology, cardiovascular diseases, and other diseases. In 2023, oncology accounted for the largest share of the mice model market. The expansion of the oncology mice model market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.

The North America region accounted for the largest share of the mice model market in 2023.

The mice model market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer and other chronic diseases has contributed to growth of the mice model market.

Key players in the mice model market Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).

Don’t miss out on business opportunities in Mice Model Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]